A model-based approach to estimating vaccine effectiveness against SARS-CoV-2 variants of concern NatureComms UNSW vaccine covid COVID19 SARSCoV2 vaccinefficacy efficacy immunity booster variants variantsofconcern VOC omicron
By Vijay Kumar MalesuJul 21 2023Reviewed by Lily Ramsey, LLM In a recent study published in Nature Communications, a group of researchers examined
However, the emergence of variants of concern has diminished the vaccines' effectiveness in preventing infection and transmission, though they still offer protection against severe outcomes. For the primary analysis, the authors used data from all age groups from studies alongside data for the >65 age group. However, there was no stratification by sex or gender in the original studies, and data on prior infection were not available, potentially biasing the vaccine effectiveness estimates.
This approach linked the IL achieved at subsequent doses to the vaccine regime used for the main course but not the time since dose 2. According to the authors' findings, mRNA-1273 exhibited the highest immune response when comparing three vaccines, followed by BNT162b2, and then AZD1222. The study also revealed that the initial period's immune level decay has a half-life of 35 days, while the subsequent decline has an estimated half-life of 581 days.
Discussion As the world faces the endemic circulation of SARS-CoV-2, understanding COVID-19 vaccine effectiveness against different variants becomes crucial.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Trypsin and anaerobic bacteria boost SARS-CoV-2 Delta variant infectivity: oral hygiene key to preventionTrypsin and anaerobic bacteria boost SARS-CoV-2 Delta variant infectivity: oral hygiene key to prevention SciReports trypsin anaerobicbacteria delta covid COVID19 SARSCoV2
Read more »
Comparing severe outcome risks of SARS-CoV-2 Omicron BA.2.75, BQ.1, BA.4.6 to BA.5Comparing severe outcome risks of SARS-CoV-2 Omicron BA.2.75, BQ.1, BA.4.6 to BA.5 medrxivpreprint COVID19 coronavirus covid Omicron
Read more »
High body temperature increases gut microbiota-dependent host resistance to influenza A virus and SARS-CoV-2 infection - Nature CommunicationsThe ambient environmental temperature changes the extent or severity of a virus infection. Here the authors show that influenza and SARS-CoV-2 infection at higher temperatures promotes gut microbiota derived deoxycholic acid signalling which increases host resistance to infection.
Read more »
Understanding persistent COVID-19 symptoms: study explores early indicators of long COVIDResearchers investigated early biomarkers of post-acute sequelae of SARS-CoV-2 infection in individuals intensively sampled during the acute phase of COVID-19.
Read more »
Famous Glasgow bars and cafes recreated by expert miniature model maker for photo projectGlasgow-based amateur photographer Katy Bridgestock has made miniatures of some of the city's most recognisable spots before taking some incredible pics of them.
Read more »
Model growth: Tesla’s ambitious plansThe carmaker, which reports results today, is still celebrating impressive growth and its boss has even bigger plans for it. But with the threat of fast-scaling competitors in the EV market, is the company losing its disruptive edge? Our data correspondent’s novel approach to counting Russian casualties in Ukraine (09:39). And, a nail-biting, ever riskier Tour de France nears its end (15:26). For full access to print, digital and audio editions of The Economist, try a free 30-day digital subscription by going to www.economist.com/intelligenceoffer Hosted on Acast. See acast.com/privacy for more information.
Read more »